The recognition, awarded by Vietnam Report, was presented to TV.Pharma, a member company of Aikya Group, on 8/1 in Hanoi.
The ranking is based on criteria of financial health and brand reputation, reflecting evaluations from financial analysts, doctors, pharmacists, and consumers. This consistent recognition for five years highlights the market and professional trust in Aikya, built upon the values the enterprise has upheld throughout its more than three decades of operation.
A company representative stated that from its inception, the company's goal extended beyond pharmaceutical manufacturing to providing comprehensive healthcare solutions for Vietnamese people.
 |
TV.Pharma, a member company of Aikya Group (top row, center), received the Top 10 Reputable Pharmaceutical Manufacturers award. Photo: Aikya |
After decades of development, the company has built a portfolio of over 600 products, including medicines, health supplements, cosmetics, and medical equipment. This portfolio is developed by its three member companies: TV.Pharma, Mebiphar, and S.Pharma.
The company also masters the pharmaceutical value chain, from research and development, manufacturing, to distribution. In research, it focuses on developing products suitable for the Vietnamese physique, addressing common illnesses, and supporting proactive healthcare trends.
In manufacturing, Aikya invests in modern factory systems that adhere to strict pharmaceutical industry standards. The group currently operates four large-scale factory clusters in Tra Vinh, Ho Chi Minh City, and Soc Trang.
TV.Pharma, the group's flagship unit, has a factory in Tra Vinh spanning approximately 30,000 square meters, operating under WHO-GMP, GLP, GSP, and GDP standards. The company is also preparing to announce its Aikya Europa factory's EU-GMP certification.
Since 2022, Aikya has boosted its production capacity through the High-Tech Pharmaceutical Industrial Cluster project in Tra Vinh, with a total investment exceeding 650 billion VND. Once completed, this cluster will have a designed capacity of approximately 3.5 billion product units annually, aiming to produce domestic medicines that meet international standards. According to a company representative, this systematic investment in factory systems ensures consistent quality for each production batch and maintains product efficacy for consumers.
Beyond manufacturing capabilities, brand reputation is also linked to a broad and transparent distribution system. The company's current distribution network covers approximately 35,000 traditional pharmacies and modern retail chains, along with over 1,500 hospitals and 1,400 clinics and medical centers nationwide.
Through this system, product groups such as antibiotics, pain relievers and fever reducers, digestive aids, respiratory treatments, musculoskeletal remedies, cardiovascular drugs, and diabetes medications are widely distributed. Some products have been honored as "National Brand" and "Vietnamese Medicine Star".
According to an Aikya representative, current achievements owe much to the collaboration of its pharmacy network and distribution partners over the past 30 years. In 2025, the company will organize a series of annual customer conferences to express gratitude to partners and share experiences in applying artificial intelligence (AI) to pharmacy management and operations.
Starting in 6/2025, the company will also implement an AI application project in business and operations, aiming to enhance work efficiency, improve product and service quality, and support data-driven decision-making.
In the upcoming phase, the company aims to develop over 1,000 treatment products and more than 100 high-quality imported products, while continuously raising quality standards and maintaining brand reputation in the domestic pharmaceutical market.
(Source: Aikya Group)
